Purpose. Infertility as a late complication of cancer chemotherapy, focusing on specific drug-related ef fects, effects observed in the treatment of certain malignancies, and strategies for prevention is re viewed.
Data Sources. A MEDLINE search of articles from 1966 to present was conducted using the terms infertility, antineoplastics, amenorrhea, azospermia, oogenesis, and spermatogenesis. Additional refer ences were identified using review articles and phar macology textbooks.
Study Selection. All human studies reported in English language were included. Animal studies were included when human data were insufficient or un available.
Data Synthesis. Data on the infertility effects of individual antineoplastic agents are difficult to inter pret for several reasons, including small sample sizes, lack of prechemotherapy fertility assessment, inade quate long-term follow-up, and use of regimens in cluding multiple agents. In general, the incidence and severity of antifertility effects are dependent on the total dosage delivered, duration of therapy, and age at exposure. The alkylating agents have the most signif icant effects on fertility. Fertility outcomes have been reported for several different malignancies, especially in patients cured of Hodgkin's disease and testicular cancer. Information on specific antineoplastic agents and cancers are reviewed. Several methods have been employed to decrease gonadotoxic effects, but none have been effective.
Conclusions. Infertility is a common late com plication of cancer chemotherapy that is receiving increasing attention as the number of cancer survi vors increases. Health care professionals should be aware of infertility risks associated with antineoplastic agents and certain malignancies, and patients should be informed of these risks as treatment decisions are made.
American Cancer Society.Cancer Facts and Figures: 1995. New York, American Cancer Society, Inc, 1995.
2.
Schilsky RL, Erlichman C. Infertility and carcinogenesis: Late complications of chemotherapy. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia : J.B. Lippincott Company; 1990:32-58.
3.
Carr BR, Wilson JDDisorders of the ovary and female reproductive tract. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine, 12th ed. New York: McGraw-Hill; 1991:1776 -1783.
4.
Griffin JE, Wilson JDDisorders of the testis. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine , 12th ed. New York: McGraw-Hill; 1991:1765-1769.
5.
Schilsky RLInfertility in patients with testicular cancer: Testis, tumor, or treatment?J Natl Cancer Inst.1989;81:1204 -1205.
6.
Smith DB, Babaian RJThe effects of treatment for cancer on male fertility and sexuality. Cancer Nurs.1992;15:271-275.
7.
Nicholson HS , Byrne J.Fertility and pregnancy after treatment for cancer during childhood or adolescence. Cancer.1993;71:3392-3399.
8.
Sieber SM, Adamson RHToxicity of antineoplastic agents in man: Chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential. Adv Cancer Res.1975;22:57-155.
9.
Byrne J.Fertility and pregnancy after malignancy. Semin Perinatol.1990;14:423- 429.
10.
Costabile RAThe effects of cancer and cancer therapy on male reproductive function. J Urol.1993;149:1327-1330.
11.
Damewood MD , Grochow LBProspects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril.1986;45:443- 459.
12.
Loescher LJ , Welch-McCaffrey D., Leigh SA, et al. Surviving adult cancers, part 1: Physiologic effects. Ann Int Med.1989;111:411- 432.
13.
Sherins RJAdverse effects of treatment: Gonadal dysfunction. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: J.B. Lippincott Company, 1993:2395-2406.
14.
Dorr RT, VonHoff DD. Cancer Chemotherapy Handbook, 2nd ed. Norwalk: Appleton and Lange, 1994.
15.
Korbitz BC, Reiquam CWBusulfan in chronic granulocytic leukemia: A spectrum of clinical considerations . Clin Med.1969;76:16-22.
16.
Belohorsky B., Siracky J., Sandor L., et al. Comments on the development of amenorrhea caused by Myeleran in cases of chronic myelosis. Neoplasma.1960;4:397- 403.
17.
Dennis LH and Stein S.Busulfan in pregnancy. JAMA.1965;192:715-716.
Richter P., Calamera JC, Morgenfield MC, et al. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer.1970; 25:1026-1030.
20.
Miller DGAlkylating agents and human spermatogenesis. JAMA.1971;217:1662-1665.
21.
Cheviakoff S., Clalmera JC, Morgenfield M., et al. Recovery of spermatogenesis in patients with lymphoma after treatment with chlorambucil. J Reprod Fertil.1973;33:155-157.
22.
Marmor D., Grob-Menendez F., Duyck F., et al. Very late return of spermatogenesis after chlorambucil therapy: Case reports. Fertil Steril.1992 ;58:845-846.
23.
Ezdinli EZ, Stutzman L.Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. JAMA.1965;191:100-106.
24.
Wallace Whb , Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum . Med Ped Oncol.1989;17:409 - 413.
25.
Maneschi F. , Benedetti-Panici P., Scambia G., et al. Menstrual and hormone patterns in women treated with high-dose cisplatin and bleomycin . Gynecol Oncol. 1994;54:345-348.
26.
Uldall PR, Kerr Dns, Tacchi D.Sterility and cyclophosphamide (letter). Lancet.1972;1:693-694.
27.
Kumar R., Biggart JD, McEnvoy J., et al. Cyclophosphamide and reproductive function. Lancet. 1972; 1:1212-1214.
28.
Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure. N EraglJ Med.1973;289:1159 -1162.
29.
DeGroot GW, Faiman C., Winter Jsd.Cyclophosphamide and the prepubertal gonad: A negative report. J Peds.1974;84:123-125.
30.
Lentz RD, Bergstein J., Steffes MW, et al. Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty. J Peds.1977;91:385-394.
31.
Koyama H., Wada T., Nishizawa Y., et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer.1977;39:1403-1409.
32.
Fairley KF, Barrie JU, Johnson W.Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet.1972;1:568 -569.
33.
Qureshi Msa , Goldsmith HJ, Pennington JH, et al. Cyclophosphamide therapy and sterility . Lancet1972; 2:1290 -1291.
34.
Rapola J., Koskimies O., Huttunen NP, et al. Cyclophosphamide and the pubertal testis (letter). Lancet. 1973;1:98 -99.
35.
Buchanan JD, Fairley KF, Barrie JUReturn of spermatogenesis after stopping cyclophosphamide therapy. Lancet. 1975;2:156 -157.
36.
Blake DA, Heller RH, Hsu SH, et al. Return of fertility in a patient with cyclophosphamide-induced azospermia. John Hopkin's MedJ.1976;139: 20-22.
37.
Spitz S.The histiological effects of nitrogen mustards on human tumors and tissues . Cancer. 1948; 1:383-398.
38.
Fisher B., Sherman B., Rockette H., et al. L-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer. Cancer. 1979;44:847- 857.
39.
Brunner KW, Young CWA methylhydrazine derivative in Hodgkin's disease and other malignant neoplasms . Ann Int Med.1965;63:69 - 86.
40.
Morris LF, Harrod MJ, Menter A., et al. Methotrexate and reproduction in men: Case report and recommendations . J Am Acad Dermatol. 1993 ;29:913-916.
41.
Sussman A., Leonard JMPsoriasis, methotrexate, and oligospermia. Arch Dermatol.1980;116:215-217.
42.
El-Beheiry A., El-Mansy E., Kamel N., et al. Methotrexate and fertility in men . Arch Androl.1979;3:177-179.
43.
Da Cunha MF , Meistrich ML, Ried HL, et al. Active sperm production after cancer chemotherapy with doxorubicin. J Urol.1983 ;130:927-930.
44.
Shenkenberg TD, Von Hoff D.Possible mitoxantrone-induced amenorrhea. Cancer Treat Rep.1986;70:659 - 661.
45.
Choo YC, Chan Syw, Wong LC, et al. Ovarian dysfunction with gestational trophoblastic neoplasia treated with short, intensive courses of etoposide (VP-16-213). Cancer. 1985;55:2348-2352.
46.
Schilsky RL , Davidson HS, Magid D., et al. Gonadal and sexual function in male patients with hairy cell leukemia: Lack of adverse effects of recombinant alpha-2-interferon treatment. Cancer Treat Rep.1987;71:179 -181.
47.
Hinkes E., Plotkin D.Reversible drug-induced sterility in a patient with acute leukemia. JAMA.1973; 223:1490-1491.
48.
Siris ES, Leventhal BG, Vaitukaitis JLEffects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med.1976;294:1143-1146.
49.
Lendon M., Hann IM, Palmer MK, et al. Testicular histology after combination chemotherapy in childhood for acute lymphoblastic leukaemia. Lancet. 1978;2:439-441.
50.
Himelstein-Braw R., Peters H., Faber M.Morphological study of the ovaries of leukaemic children. BrJ Cancer. 1978;38:82-87.
51.
Lilleyman JSMale fertility after successful chemotherapy for lymphoblastic leukemia (letter). Lancet. 1979;2:1125.
52.
Matthews JH , Wood JKMale fertility during chemotherapy for acute leukemia (letter). N Engl J Med.1980;303:1235.
53.
Shalet SM, Hann IM, Lendon M., et al. Testicular function after combination chemotherapy in childhood for acute lymphoblastic leukemia. Arch Dis Child.1981;56:275-278.
54.
Blatt J., Poplack DG, Sherins RJTesticular function in boys after chemotherapy for acute lymphoblastic leukemia . N Engl J Med.1981;304:1121-1124.
55.
Maguire LC, Dick FR, Sherman BMThe effects of anti-leukemic therapy on gonadal histology in adult males. Cancer.1981;48:1967-1971.
56.
Kuhajda FP, Haupt HM, Moore GW, et al. Gonadal morphology in patients receiving chemotherapy for leukemia: Evidence for reproductive potential and against a testicular tumor sanctuary . Am J Med.1982:72:759-767.
57.
Evenson DP, Arlin Z., Welt S., et al. Male reproductive capacity may recover following drug treatment with the L-10 protocol for acute lymphocytic leukemia. Cancer.1984; 53:30 -36.
58.
Muller J., Skakkebaek NE, Hertz H.Initiation of spermatogenesis during chemotherapy for leukemia. Acta Paediatr Scand.1985;74:956-960.
59.
Kreuser ED, Hetzel WD, Heit W., et al. Reproductive and endocrine gonadal functions in adults following multidrug chemotherapy for acute lymphoblastic or undifferentiated leukemia . J Clin Oncol.1988;6:588-595.
60.
Quigley C., Cowell C., Jimenez M., et al. Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. N Engl J Med.1989;321:143-151.
61.
Marcello MF , Nuciforo G., Romeo R., et al. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer.1990; 66:2099-2104.
62.
Nygaard R., Clausen N., Siimes MA, et al. Reproduction following treatment for childhood leukemia: A population-based prospective cohort study of fertility and offspring. Med Ped Oncol.1991;19:459 - 466.
63.
Liesner R., Leiper AD, Hann IM, et al. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol.1994; 12:916 -924.
64.
Rose DP, Davis TEOvarian function in patients receiving adjuvant chemotherapy for breast cancer . Lancet. 1977;1:1174 -1175.
65.
Samaan NA, DeAsis DN, Buzdar AU, et al. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer.1978;41:2084- 2087.
66.
Schulz KD, Schmidt-Rhode P., Weymar P., et al. The effect of combination chemotherapy on ovarian, hypothalamic, and pituitary function in patients with breast cancer. Arch Gynecol.1979 ;227:293-301.
67.
Dnistrian AM , Schwartz MK, Fracchia AA, et al. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer.1983; 51:803- 807.
68.
Dnistrian AM , Greenberg EJ, Dillon HJ, et al. Chemohormonal therapy and endocrine function in breast cancer patients. Cancer.1985;56:63-70.
69.
Delrio G., De Placido S., Pagliarulo C., et al. Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori.1986;72:53-61.
70.
Sutton R., Buzdar AU, Hortobagyi GNPregnancy and offspring after adjuvant chemotherapy in breast cancer patients . Cancer.1990;65:847- 850.
71.
Reyno LM, Levine MN, Skingley P., et al. Chemotherapy-induced amenorrhoea in a randomized trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer. 1993;29A:21-23.
72.
Valagussa P. , Moliterni A., Zambetti M., et al. Long-term sequelae from adjuvant chemotherapy. Rec ResultsCancer Res.1993;127:247-255.
73.
Himelstein-Braw R., Peters H., Faber M.Influence of irradiation and chemotherapy on the ovaries of children with abdominal tumours. Br J Cancer.1977; 36: 269 -275.
74.
Nicosia SV, Matus-Ridley M., Meadows ATGonadal effects of cancer therapy in girls. Cancer.1985;55: 2364 -2372.
75.
Jaffe N., Sullivan MP, Ried H., et al. Male reproductive function in long-term survivors of childhood cancer. Med Ped Oncol.1988;16:241-247.
76.
Clayton PE, Shalet SM, Price DA, et al. Ovarian function following chemotherapy for childhood brain tumors. Med Ped Oncol.1989;17:92-96.
77.
Matus-Ridley M., Nicosia SV, Meadows ATGonadal effects of cancer therapy in boys . Cancer.1985;55: 2353-2363.
78.
Byrne J., Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med.1987;317:1315-1321.
79.
Byrne J., Fears TR, Gall MH, et al. Early menopause in long-term survivors of cancer during adolescence . Am J Obstet Gynecol.1992;166:788 -793.
80.
Schilsky RLMale fertility following cancer chemotherapy . J Clin Oncol.1989;7:295-297.
81.
Sobrinho LG , Levine RA, DeConti RCAmenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol.1971; 109:135-139.
82.
Morgenfield MC, Goldberg V., Parisier H., et al. Ovarian lesions due to cytostatic agents during the treatment of Hodgkin's disease. Surg Gynecol Obstet.1972;134:826-828.
83.
Chapman RM, Sutcliffe SB, Malpas JSCytotoxic-induced ovarian failure in women with Hodgkin's disease: Hormone function. JAMA.1979 ;242:1877-1881.
84.
Johnson SA, Golman JM, Hawkins DFPregnancy after chemotherapy for Hodgkin's disease (letter). Lancet.1979;2:93.
85.
Rostom AY, White WFHodgkin's disease, chemotherapy, and fertility (letter). Lancet. 1979;1:555.
86.
Horning SJ, Hoppe RT, Kaplan HS, et al. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med.1981; 304:1377-1382.
87.
Schilsky RL , Sherins RJ, Hubbard SM, et al. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med.1981;71:552-556.
88.
Green DM, Brecher ML, Lindsay AN, et al. Gonadal function in pediatric patients following treatment for Hodgkin's disease. Med Ped Oncol.1981;9:235-244.
89.
Waxman Jhx, Terry YA, Wrigley Pfm, et al. Gonadal function in Hodgkin's disease: Long-term follow-up of chemotherapy. Br Med J1982;285: 1612-1613.
90.
Andrieu JM, Ochoa-Molina ME. Menstrual cycle, pregnancies, and offspring before and after MOPP therapy for Hodgkin's disease. Cancer.1983;52:435-438.
91.
Whitehead E., Shalet SM, Blackledge G., et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer.1983;52:988-993.
92.
Fisher B., Cheung Ayc.Delayed effect of radiation therapy with or without chemotherapy on ovarian function in women with Hodgkin's disease. Acta Radiologica Oncol.1984;23:43-48.
93.
King DJ, Ratcliffe MA, Dawson AA, et al. Fertility in young men and women after treatment for lymphoma: A study of a population. J Clin Pathol.1985 ;38:1247-1251.
94.
Lacher MJ, Toner K.Pregnancies and menstrual function before and after combined radiation (RT) and chemotherapy (TVPP) for Hodgkin's disease. Cancer Invest.1986;4:93-100.
95.
Kreuser ED, Xiros N., Hetzel WD, et al. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol.1987;113:260 -266.
96.
Ortin Tts, Shostak CA, Donaldson SSGonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford experience. Int j Radiation Oncol Biol Phys.1990;19:873-880.
97.
Clark ST, Radford JA, Crowther D., et al. Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol.1995;13:134 -139.
98.
Hill M., Milan S., Cunningham D., et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol.1995;13:387-395.
99.
Sherins RJ, Olweny Clm, Ziegler JLGynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease. N Engl J Med.1978;299:12-16.
100.
Chapman RM , Sutcliffe SB, Rees LH, et al. Cyclical combination chemotherapy and gonadal function. Lancet. 1979;1:285-289.
101.
Stricker S. , Crosby K., Carey RW, et al. Paternity after chemotherapy-induced sterility in Hodgkin's disease (letter). N Engl J Med.1981;304:1175.
102.
Ramona Maj , Chapman M., Sutcliffe SB, et al. Male gonadal dysfunction in Hodgkin's disease: A prospective study. JAMA.1981;245:1323-1328.
103.
Vigersky RA , Chapman RM, Berenberg J., et al. Testicular dysfunction in untreated Hodgkin's disease. Am J Med.1982;73:482-486.
104.
Whitehead E., Shalet M., Blackledge G., et al. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer.1982;49:418-422.
105.
Epenetos AARecovery of testicular function after chemotherapy: A case report. Anticancer Res.1984;4:203.
106.
Da Cunha MF , Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol.1984;2:571-577.
107.
Viviani S. , Santoro A., Ragni G., et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP versus ABVD . Eur J Cancer Clin Oncol.1985;21:601-605.
108.
Bramswig JH , Heimes U., Heiermann E., et al. The effects of different cumulative doses of chemotherapy on testicular function: Results of 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer.1990;65:1298 -1302.
109.
Viviani S. , Ragni G., Santoro A., et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer. 1991; 27:1389 -1392.
110.
Shafford EA , Kingston JE, Malpas JS, et al. Testicular function following the treatment of Hodgkin's disease in childhood. Br J Cancer.1993;68:1199 -1204.
111.
Sherins RJ , DeVita VTEffect of drug treatment for lymphoma on male reproductive capacity: Studies of men in remission after therapy. Ann Int Med.1973;79:216 -220.
112.
Roeser HP, Stocks AE, Smith AJTesticular damage due to cytotoxic drugs and recovery after cessation of therapy . Aust NZ J Med.1978;8:250 -254.
113.
Wang C., Ng RP, Chan TK, et al. Effect of combination chemotherapy on pituitary-gonadal function in patients with lymphoma and leukemia. Cancer.1980;45:2030 -2037.
114.
Pryzant RM , Meistrich ML, Wilson G., et al. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas . J Clin Oncol.1993;11:239 -247.
115.
Carlson RW , Sikic BI, Turbow MM, et al. Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary . J Clin Oncol.1983;1:645- 651.
116.
Davis Tee, Loprinzi CL, Buchler DACombination chemotherapy with cisplatin, vinblastine, and bleomycin for endodermal sinus tumor of the ovary. Gynecol Oncol. 1984 ;19:46 -52.
117.
Pektasides D. , Rustin Gjs, Newlands ES, et al. Fertility after chemotherapy for ovarian germ cell tumours. Br jObstet Gynecol.1987 ;94:477- 479.
118.
Gershenson DMMenstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol.1988;6:270 -275.
119.
Shamberger RC, Rosenberg SA, Seipp CA, et al. Effects of high-dose methotrexate and vincristine on ovarian and testicular function in patients undergoing postoperative adjuvant treatment for osteosarcoma. Cancer Treat Rep.1981;65:739-746.
120.
Meistrich ML, Chawla SP, Da Cunha F., et al. Recovery of sperm production after chemotherapy for osteosarcoma. Cancer1989 ;63:2115-2123.
121.
Nicholson HS, Mulvihill JJ, Byrne J.Late effects of therapy on adult survivors of osteosarcoma and Ewing's sarcoma. Med Ped Oncol.1992;20:6 - 12.
122.
Shamberger RC, Sherins RJ, Ziegler JL, et al. Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. J Natl Cancer Inst.1981;67:1213-1218.
123.
Shamberger RC, Sherins RJ, Rosenberg SAThe effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma. Cancer.1981 ;47:2368-2374.
124.
Bianchi DW , Garcea RLSuccessful pregnancy in an adolescent with metastatic undifferentiated sarcoma: A case report. J Reprod Med.1987; 32:76 -78.
125.
Meistrich ML, Wilson G., Brown BW, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer.1992 ;11:2703-2712.
126.
Berthelsen JG, Skakkebaek NEGonadal function in men with testis cancer . Fertil Steril.1983;39:68-75.
127.
Sanger WG, Armitage JO, Schmidt MAFeasibility of semen cryopreservation in patients with malignant disease. JAMA.1980;244:789-790.
128.
Bracken RB , Smith KDIs semen cryopreservation helpful in testicular cancer? Urology.1980;15: 581-583.
129.
Lange PH, Narayan P., Vogelzang NJ, et al. Return of fertility after treatment for nonseminomatous testicular cancer: Changing concepts. jUrol. 1983; 129:1131-1135.
130.
Drasga RE, Einhorn LH, Williams SD, et al. Fertility after chemotherapy for testicular cancer. J Clin Oncol.1983;1:179 -183.
131.
Rubery EDReturn of fertility after curative chemotherapy for disseminated teratoma of the testis (letter). Lancet. 1983 ; 1: 186.
132.
Berthelsen JGSperm counts and serum follicle-stimulating hormone levels before and after radiotherapy and chemotherapy in men with testicular germ cell cancer. Fertil Steril.1984;41:281-286.
133.
Fossa SD, Ous S., Abyholm T., et al. Post-treatment fertility in patients with testicular cancer: Influence of cis-platin based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol.1985;57:210 -214.
134.
Brenner J. , Vugrin D., Whitmore WFEffect of treatment on fertility and sexual function in males with metastatic nonseminomatous germ cell tumors of testis . Am J Clin Oncol.1985;8:178 -182.
135.
Leitner SP , Bosl GJ, Bajorunas D.Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol.1986;4:1500-1505.
136.
Kreuser ED , Harsch U., Hetzel WD, et al. Chronic gonadal toxicity in patients with testicular cancer after chemotherapy. Eur J Cancer Clin Oncol.1986;22:289 -294.
137.
Nijman JM, Koops HS, Kremer J., et al. Gonadal function after surgery and chemotherapy in men with stage II and III nonseminomatous testicular tumors. J Clin Oncol.1987; 5:651- 656.
138.
Hansen PV, Trykker H., Helkjaer PE, et al. Testicular function in patients with testicular cancer treated with orchiectomy alone or orchiectomy plus cisplatin-based chemotherapy. J Natl Cancer Inst.1989;81:1246-1250.
139.
Hansen SW, Berthelsen JG, Von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol.1990;8:1695-1698.
140.
Sanders JE , Buckner CD, Leonard JM, et al. Late effects on gonadal function of cyclophosphamide, total body irradiation, and marrow transplantation. Transplantation.1983;36:252-255.
141.
Sanders JE , Pritchard S., Mahoney P., et al. Growth and development following marrow transplantation for leukemia. Blood.1986;68:1129-1135.
142.
Sanders JE , Buckner CD, Amos D., et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol.1988;6: 813-818.
143.
Cohen A., Lavagetto A., Chiodi S., et al. Pubertal development and fertility in children after bone marrow transplantation. Bone Marrow Transplant.1991 ;(suppl):16 -21.
144.
Jacob A., Goodman A., Holmes J.Fertility after bone marrow transplantation following conditioning with cyclophosphamide and total body irradiation. Bone Marrow Transplant.1995;15:483- 484.
145.
Myers SE, Schilsky RLProspects for fertility after cancer chemotherapy. Semin Oncol.1992;19:597-604.
146.
Waxman JH, Ahmed R., Smith D., et al. Failure to preserve fertility in patients with Hodgkin's disease . Cancer Chemother Pharmacol.1987;19:159 -162.
147.
Chapman RM , Sutcliffe SBProtection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's Disease. Blood.1981;58:849-851.
148.
Horstman MG , Meadows GG, Yost GSSeparate mechanisms for procarbazine spermatotoxicity and anticancer activity. Cancer Res.1987;47:1547-1550.
149.
Nonomura M. , Okada K., Hida S., et al. Does a gonadotropin-releasing hormone analogue prevent cisplatin-induced spermatogenic impairment? An experimental study in the mouse. Urol Res. 1991; 19:135-140.
150.
Ward JA, Robinson J., Furr Bja, et al. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist . Cancer Res.1990;50:568-574.
151.
Kreuser ED , Klingmuller D., Thiel E.The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation. Eur Urol.1993;23:157-164.
152.
Glode LM, Robinson J., Gould SFProtection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981;1:1132-1134.
153.
Handelsman DJ, Peng S., Sikka S., et al. Effects of gonadotropin-releasing hormone analogs on cis-platinum-induced spermatogenic damage. Internatl J Androl.1988;11:425- 435.
154.
Johnson DH , Linde R., Hainsworth JR, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on post-therapy fertility in male patients with lymphoma: Preliminary observations. Blood.1985;4:832- 836.
155.
Krause W., Pfluger KHTreatment with the gonadotropin-releasing hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia. 1989;21:265-270.
156.
Krueser ED , Hetzel WD, Hautmann R., et al. Reproductive toxicity with and without LHRHa administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res.1990;22: 494 -498.
157.
Parchuri N. , Wilson G., Meistrich MLProtection by gonadal steroid hormones against procarbazine-induced damage to spermatogenic function in LBNF1 hybrid rats . J Androl.1993;14:257-266.
158.
De la Calle Jfv, Jegou B.Protection by steroid contraceptives against procarbazine-induced sterility and genotoxicity in male rats. Cancer Res.1990; 50:1308 -1315.
159.
Morris ID, Bardin CW, Gunsalus G., et al. Prolonged suppression of spermatogenesis by oestrogen does not preserve the seminiferous epithelium in procarbazine-treated rats. Internat J Androl.1990;13: 180-9.
160.
Weissenberg R., Lahav M., Raanani P., et al. Clomiphene citrate reduces procarbazine-induced sterility in a rat model. Br J Cancer.1995 ;71:48 -51.
161.
Fossa SD, Kleep O., Norman N.Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. Br J Urol.1988;62: 449 - 453.
162.
Gibbons JJ , Parra RO, Andriole GL, et al. Testicular circulatory isolation: A phase I study. Surg Oncol. 1992;1:413- 416.
163.
Kaempfer SHThe effects of cancer chemotherapy on reproduction: A review of the literature. Oncol Nurs Forum.1981;8:11-18.
164.
Rhodes EA, Hoffman DJ, Kaempfer SHTen years of experience with semen cryopreservation by cancer patients: Follow-up and clinical considerations. Fertil Steril.1985;44:512-516.
165.
Scammell GE , White N., Stedronska J., et al. Cryopreservation of semen in men with testicular tumour or Hodgkin's disease: Results of artificial insemination of their partners. Lancet. 1985;2:31-32.
166.
Reed E., Sanger WG, Armitage JOResults of semen cryopreservation in young men with testicular carcinoma and lymphoma. J Clin Oncol.1986;4:537-539.
167.
Redman JR, Bajorunas DR, Goldstein MC, et al. Semen cryopreservation and artificial insemination for Hodgkin's disease. J Clin Oncol.1987 ;5:233-238.
168.
Tournaye H. , Wisanto A., Camus M., et al. In vitro fertilization techniques with frozen-thawed sperm: A method for preserving the progenitive potential of Hodgkin patients. Fertil Steril.1991 ;55:443-445.
169.
Shekarriz M., Tolentino MV, Ayzman I., et al. Cryopreservation and semen quality in patients with Hodgkin's disease. Cancer.1995;75:2732-2736.
170.
Davis OK, Graf MJ, Bedford JM, et al. Pregnancy achieved through in vitro fertilization with cryopreserved semen from a man with Hodgkin's lymphoma. Fertil Steril.1990;53:377-378.
171.
Parrish RHCancer chemotherapy and contraceptive counseling . Drug Intel Clin Pharm.1984;18: 71-72.
